Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Debate Could Provide Clarity On Use Of Progression-Free Survival Endpoints

Executive Summary

Rather than damaging the use of progression-free survival as an endpoint in oncology clinical trials, as some have feared, the battle over Avastin’s (bevacizumab) metastatic breast cancer claim could give sponsors some clarity as to how FDA expects the magnitude of PFS benefit to be defined.
Advertisement

Related Content

Surrogate Endpoints Only Have ‘Limited’ Evidence On Cancer Survival, Review Concludes
AstraZeneca Takes “Anti-Avastin” Pledge On Accelerated Approval Withdrawal
Industry Presses FDA For More Specificity On Lung Cancer Study Endpoints
Avastin Breast Cancer Approval Memo Comes Back To Haunt FDA’s Pazdur
Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns
Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns
Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?
After Avastin, Seeking Clarity On Progression-Free Survival Endpoints
Accelerated Approval Remains “Viable Pathway,” FDA’s Woodcock Says
Avastin Breast Cancer Dispute Centers On “Magnitude Of Benefit” Questions

Topics

Advertisement
UsernamePublicRestriction

Register

PS053575

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel